Stephens & Co. Reiterates Overweight on Actinium Pharma, Maintains $5 Price Target
Actinium Pharmaceuticals, Inc. +10.77% Pre
Actinium Pharmaceuticals, Inc. ATNM | 1.44 1.50 | +10.77% +4.23% Pre |
Stephens & Co. analyst Sudan Loganathan reiterates Actinium Pharma (AMEX:
ATNM) with a Overweight and maintains $5 price target.
